11:43 AM EST, 11/04/2024 (MT Newswires) -- Royal Philips (PHG) said Monday it enrolled the first patient in a clinical trial, studying a new catheter that combines laser atherectomy and intravascular lithotripsy for treating peripheral artery disease.

The Cardiovascular Institute of the South in Louisiana successfully treated a 78-year-old man with peripheral vascular disease using the new Philips laser catheter, the company said.

The trial aims to enroll up to 155 patients at 30 US sites.

The study's primary endpoints are freedom from major adverse events within 30 days and achieving 50% or less residual stenosis after the procedure, with a 12-month patient follow-up, the company said.

Shares of Royal Philips were up 2.6% in recent trading.

Price: 27.19, Change: +0.70, Percent Change: +2.62